Risk of lymphoma increases with hepatitis C virus infectionMay 09, 2007People infected with the hepatitis C virus (HCV) are at an increased risk of developing certain lymphomas (cancers of the lymphatic system), according to a study published in the May 8, 2007, issue of the Journal of the American Medical Association. Researchers from the National Cancer Institute (NCI), part of the National Institutes of Health, and Baylor College of Medicine, found that HCV infection increased the risk of developing non-Hodgkin's lymphoma by 20 percent to 30 percent. The risk of developing Waldenström's macroglobulinemia (a rare type of non-Hodgkin's lymphoma) went up by 300 percent and the risk for cryoglobulinemia, a condition marked by abnormal levels of certain antibodies in the blood, was also elevated for those with HCV infections. The researchers looked at patient records collected from Veterans Affairs (VA) hospitals across the United States between 1996 and 2004. Researchers selected more than 700,000 records; 146,394 represented patients who were diagnosed with the hepatitis C virus, while 572,293 represented patients who were not. Based on that review, researchers determined, first, that the patients infected with HCV had a higher risk of developing lymphoma and, second, that HCV infection preceded development of the lymphoma. The risk of lymphomas in HCV-infected patients was charted across more than five years of follow-up. "This is one of the largest studies ever conducted to look at the relationship between hepatitis C virus infection and cancers of the lymphatic system," said NCI Director John E. Niederhuber, M.D. "Since so much is still unknown about the causes of lymphoma, establishing which factors contribute to the disease is the first step in finding ways to reduce its incidence and lessen mortality." HCV causes hepatitis, which is an inflammation of the liver. The HCV virus is carried through the blood and is passed from person to person through the exchange of bodily fluids -- via shared needles, open wounds, and sexual contact, among other means. HCV is also known to cause cirrhosis and liver cancer. "Although the risk of developing lymphomas is small, our research suggests that screening of HCV-infected individuals could identify conditions which may lead to cancer. It might then be possible to prevent progression to lymphoma," said investigator Eric A. Engels, M.D., from the Viral Epidemiology Branch of NCI's Division of Cancer Epidemiology and Genetics. "More research is needed to further clarify the relationship between HCV infection and lymphoma." In the United States, there are more than 4.1 million people living with hepatitis C virus infection -- about 1.6 percent of the population. In 2007, it is estimated that 71,380 Americans will be diagnosed with some type of lymphoma, which will take 19,730 lives. The researchers note that this study was limited to military veterans who used the VA system, so the results may not be applicable to the overall U.S. population. The study population was mostly men (97 percent), the majority of patients were white, and the average age was 52 years. Patients in the HCV-infected group were more likely to have served during the Vietnam era (1964-1975) than were uninfected patients in the comparison group. Previous studies found that the prevalence of HCV infection is much higher among U.S. veterans who use the VA medical system (5 percent) than in the general population, where only 1.6 percent carry the virus. Several factors have likely contributed to this higher prevalence, including demographics, socioeconomic status, and particularly a history of injection drug use or blood transfusions received before 1990, when screening for hepatitis C virus was started. NIH/National Cancer Institute |
|||||||||||||||||||||
| Related Hepatitis Current Events and Hepatitis News Articles Researchers find 'broad spectrum' antiviral that fights multitude of viruses Viruses are insidious creatures. They differ from each other in many ways, and they can mutate - at times seemingly at will, as with HIV - to resist a host of weapons fired at them. Complicating matters further is that new viruses are constantly emerging. Virus-like particle vaccine protects monkeys from chikungunya virus An experimental vaccine developed using non-infectious virus-like particles (VLP) has protected macaques and mice against chikungunya virus, a mosquito-borne pathogen that has infected millions of people in Africa and Asia and causes debilitating pain, researchers at the National Institutes of Health have found. Treatment for chronic hepatitis C: A phase II study The current standard treatment for chronic hepatitis C with pegylated-interferon (PEG-IFN) and ribavirin is effective in approximately 50%-60% of patients, so that a substantial proportion of patients remain unresponsive. Prognosis of intrahepatic cholangiocarcinoma Incidence of intrahepatic cholangiocarcinoma (ICC) is increasing worldwide and its prognosis is very poor. Thus, further studies on its clinical characteristics for early detection and on surgical treatment for better prognosis are urgently needed. A novel and simple formula to predict treatment success in chronic hepatitis C The likelihood of treatment success of 48 wk peg-interferon (PEG-IFN) plus ribavirin (RBV) therapy for chronic hepatitis C may be predicted by viral kinetics on therapy. IOM report recommends steps to tackle hepatitis B and C Stepped-up vaccination requirements, a boost in resources for prevention and treatment, and a public awareness campaign similar to the effort that dispelled the stigma of HIV/AIDS are needed to curb the health threats posed by hepatitis B and hepatitis C, says a new report from the Institute of Medicine. Chlorophylls effective against aflatoxin A new study has found that chlorophyll and its derivative chlorophyllin are effective in limiting the absorption of aflatoxin in humans. Heme channel found In some ways a cell in your body or an organelle in that cell is like an ancient walled town. Life inside either depends critically on the intelligence of the gatekeepers. UCLA researchers demonstrate that stem cells can be engineered to kill HIV Researchers from the UCLA AIDS Institute and colleagues have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells - a process that potentially could be used against a range of chronic viral diseases. Toward explaining why hepatitis B hits men harder than women Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women. More Hepatitis Current Events and Hepatitis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||